--- canonical_name: Tangeretin alternate_names: Tangeritin, Ponkanetin, 4',5,6,7,8-pentamethoxyflavone, 5,6,7,8,4'-pentamethoxyflavone, 5,6,7,8-tetramethoxy-2-(4-methoxyphenyl)chromen-4-one canonical_topic: Tangeretin for Health & Longevity short_topic_lc: tangeretin creation_date: 2026-0923-1014 creator_ai_fullname: Opus 5.5 ep_keywords: Polymethoxyflavones, Citrus Flavonoids, Flavonoids --- # Tangeretin for Health & Longevity
Evidence Review created on 09/23/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 5.5 **Also known as:** Tangeritin, Ponkanetin, 4',5,6,7,8-pentamethoxyflavone, 5,6,7,8,4'-pentamethoxyflavone, 5,6,7,8-tetramethoxy-2-(4-methoxyphenyl)chromen-4-one ## Motivation Tangeretin (tangeritin) is a plant compound concentrated in the peel of tangerines, mandarins and oranges. It belongs to a small family of citrus-peel compounds whose chemical structure lets them pass into cells more easily than most plant pigments, and in laboratory studies it quiets the switches inside cells that drive inflammation. Dried mandarin peel has long been used in East Asian cooking and traditional medicine, and tangeretin is one of its main active ingredients. Animal studies link it to steadier blood sugar, protection of brain cells and longer life in worms, and the first small human studies, in athletes and in older adults, have appeared only recently. At the same time, laboratory and animal work suggests it can change how the body handles some medicines, including a widely used breast cancer drug. This review examines what human, animal and laboratory evidence shows about tangeretin as a supplement for health-focused adults: the benefits reported so far, the risks and drug interactions, how it has been taken in studies, and where the evidence remains thin. **[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)** ## Recommended Reading This section lists narrative reviews that give a high-level overview of tangeretin's biology, effects and absorption. - [Prospects of tangeretin as a modulator of cancer targets/pathways](https://pubmed.ncbi.nlm.nih.gov/32942013/) - Raza et al., 2020 Maps tangeretin's anticancer actions in cells and animals and summarizes its absorption and toxicity data, useful for weighing laboratory promise against the absence of human cancer trials. - [Tangeretin: a mechanistic review of its pharmacological and therapeutic effects](https://pubmed.ncbi.nlm.nih.gov/32329752/) - Ashrafizadeh et al., 2020 Broad survey of reported antioxidant, anti-inflammatory, liver, brain and metabolic effects, organized by the cell signaling routes tangeretin influences. - [Beneficial Effects of Citrus-Derived Polymethoxylated Flavones for Central Nervous System Disorders](https://pubmed.ncbi.nlm.nih.gov/33406641/) - Matsuzaki & Ohizumi, 2021 Reviews animal evidence that tangeretin and its sister compound nobiletin protect memory and nerve cells, written by researchers who later tested citrus-peel products in older adults. - [Progress of Researches on Pharmacological Effects and Bioavailability of Tangeretin](https://pubmed.ncbi.nlm.nih.gov/39756989/) - Wang et al., 2025 Explains tangeretin's poor water solubility and low oral absorption, and reviews emulsion and encapsulation methods designed to raise the amount reaching the bloodstream. Only four items are listed. Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser and Lifespan.io have published no content on tangeretin (site searches returned no matches). Life Extension mentions it only briefly, in a 2024 news item on antioxidants for soccer players and in a reference within a nobiletin article; neither discusses tangeretin in depth, so neither is listed. Remaining candidate reviews repeated the anticancer and brain coverage above, so the list was not padded. ## Grokipedia [Tangeretin](https://grokipedia.com/page/tangeretin) AI-generated encyclopedia entry covering tangeretin's chemistry, citrus sources, laboratory effects and rodent safety data; it acknowledges that human trials remain limited. ## Examine No Examine article on tangeretin exists. The site's search returns only two short study summaries in its research feed, both covering the athlete trials discussed under Expected Benefits. ## ConsumerLab No ConsumerLab article on tangeretin exists. ## Systematic Reviews This section lists systematic reviews that include tangeretin; all are based on laboratory and animal studies rather than human trials. - [Citrus peel derived poly-methoxylated flavones (PMF)](https://pubmed.ncbi.nlm.nih.gov/34039010/) - Vajdi & Farhangi, 2023 Sixteen animal and cell studies: citrus-peel flavones, tangeretin included, reduced weight gain, blood fats and insulin resistance. No human trial qualified. - [Citrus Flavonoids as Promising Phytochemicals Targeting Diabetes and Related Complications: A Systematic Review of In Vitro and In Vivo Studies](https://pubmed.ncbi.nlm.nih.gov/32977511/) - Gandhi et al., 2020 Thirty-eight laboratory and animal studies of nineteen citrus flavonoids, tangeretin included, showing blood-sugar benefits; the authors state human confirmation is lacking. - [Citrus flavonoids as potential therapeutic agents: A review](https://pubmed.ncbi.nlm.nih.gov/34626134/) - Alam et al., 2022 Systematic catalog of flavonoids from the citrus plant family, tangeretin included, summarizing anticancer, anti-inflammatory and antidiabetic activity from preclinical work. No systematic review or meta-analysis covers tangeretin's principal risk, its effects on drug handling (including the tamoxifen interaction); that side of the trade-off is unrepresented in this section. ## Mechanism of Action Tangeretin is a flavone carrying five methoxy groups (small carbon caps replacing hydroxyl groups), making it fat-soluble so it crosses cell membranes and, in rodents, the blood-brain barrier. It is not selective, acting on several signaling hubs at once: - **Inflammation and antioxidant defense:** suppresses NF-κB (a master switch for inflammatory genes) and activates Nrf2 (a switch for the cell's antioxidant defense genes). - **Metabolism:** activates AMPK (the cell's energy sensor), raising glucose uptake in muscle cells, and inhibits SGLT1 (the gut transporter that absorbs glucose). - **Cell growth and spread:** dampens PI3K/Akt (a growth and survival signaling pathway) and strengthens E-cadherin (a protein binding cells together), slowing cancer cell division and invasion. - **Platelets:** blocks platelet activation, reducing clot formation in the laboratory. - **Worm aging:** extends worm lifespan through the insulin/IGF-1 pathway (IGF-1: insulin-like growth factor 1, a growth signal). A competing view: cell studies mostly use 10–100 micromolar concentrations, whereas rat blood peaked near 2 micromolar after a large oral dose ([Hung et al., 2018](https://pubmed.ncbi.nlm.nih.gov/29567257/)), so laboratory effects may overstate what supplements achieve. Pharmacology: in rats, oral bioavailability (share of a dose reaching the blood) is about 27%, half-life (time for blood levels to halve) about 5.7 hours, and tissue levels peak in kidney, lung and liver ([Hung et al., 2018](https://pubmed.ncbi.nlm.nih.gov/29567257/)). Metabolism runs mainly through CYP1A2 (a liver enzyme that clears caffeine and many drugs), with CYP3A4 (the enzyme clearing about half of prescription drugs) contributing ([Breinholt et al., 2003](https://pubmed.ncbi.nlm.nih.gov/12828569/)). Human half-life has not been measured. ## Historical Context & Evolution Tangeretin was first isolated from tangerine peel in the 1930s. The pure compound had no original medical use; its main historical exposure route is dried mandarin peel (chenpi), used in traditional Chinese medicine for digestion and cough, in which tangeretin is a principal flavone. - **1970s:** University of Florida researcher Robert Robbins reported that citrus methoxylated flavones reduced blood cell clumping in human blood, proposing a dietary role in disease resistance ([Robbins, 1975](https://pubmed.ncbi.nlm.nih.gov/1140899/)). - **1990s:** A Ghent University group found tangeretin blocked breast cancer cell growth and invasion in culture, yet in mice it abolished tamoxifen's tumor control ([Bracke et al., 1999](https://pubmed.ncbi.nlm.nih.gov/10050869/)), recasting a cancer candidate as a potential interaction hazard. - **2000s:** Hamster studies by Canadian developer KGK Synergize (a financial conflict of interest) showed tangeretin-rich citrus-peel flavones lowered cholesterol ([Kurowska & Manthey, 2004](https://pubmed.ncbi.nlm.nih.gov/15137829/)), leading to its commercial blend Sytrinol. A trial run by authors affiliated with its distributor and developer (a financial conflict of interest) reported large cholesterol reductions ([Roza et al., 2007](https://pubmed.ncbi.nlm.nih.gov/17985810/)); a larger independent trial found no effect beyond placebo ([Schuchardt et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25828621/)). - **2010s–2020s:** Interest moved to metabolism, brain protection and body-clock biology, and in 2021–2022 the first small human trials of tangeretin alone appeared in athletes. What changed: early optimism came from cell studies; animal work added an interaction warning; human trials added a null independent cholesterol result and small positive signals in athletes. None of these findings is settled, and the tamoxifen concern has never been tested in people. ## Expected Benefits ### High 🟩 🟩 🟩 No benefit reaches High: no outcome has been reproduced in more than one independent human trial, and the few human trials are small, short, and mostly test tangeretin inside multi-ingredient products. ### Medium 🟩 🟩 No benefit reaches Medium: no single trial of tangeretin alone has measured a clinical outcome (symptoms, events or function) or a validated surrogate (a lab marker proven to predict such outcomes); the athlete trials measured stress hormones and body composition, and trials with clinical endpoints tested tangeretin inside mixtures. ### Low 🟩 #### Lower Cortisol Response to Intense Training ⚠️ Conflicted In a 4-week RCT (participants assigned by chance to treatment or placebo) of 24 soccer players, 200 mg/day tangeretin lowered cortisol and ACTH (the pituitary hormone triggering cortisol) after heavy lifting ([Liu et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35665223/)). A whey-controlled sprinter RCT found no cortisol difference ([Cao et al., 2026](https://pubmed.ncbi.nlm.nih.gov/41509539/)). Net reading: unconfirmed. **Magnitude:** At week 4, serum cortisol was lower than placebo before and 10 minutes after a heavy lifting session, and ACTH 30 minutes after; the soccer trial reports these differences only as p-values (the probability that a difference arose by chance), with no effect-size figure (a number showing how large the difference was), and the sprinter trial found no between-group cortisol difference. #### Body Composition and Strength ⚠️ Conflicted Tangeretin plus whey raised sprinters' fat-free mass beyond controls ([Liu et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34821105/); [Cao et al., 2026](https://pubmed.ncbi.nlm.nih.gov/41509539/)). Tangeretin alone left soccer players' muscle, fat and strength unchanged ([Liu et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35665223/)), and a juice-company-co-authored enriched-juice trial added no weight loss ([Navajas-Porras et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40597485/)). Net reading: small, inconsistent effect. **Magnitude:** Fat-free mass rose 2.3% with tangeretin plus whey versus 1.1% with whey alone over 4 weeks; the soccer and juice trials found no between-group difference. #### Less Exercise-Induced Airway Narrowing In 30 professional athletes with exercise-induced bronchoconstriction (airway narrowing triggered by exercise), 4 weeks of tangeretin plus whey protein reduced post-exercise lung-function decline and inflammation markers versus placebo ([Cao et al., 2024](https://pubmed.ncbi.nlm.nih.gov/39422600/)). The placebo lacked whey, so tangeretin's own contribution is uncertain. **Magnitude:** 6 of 15 athletes (40%) no longer met criteria for exercise-induced bronchoconstriction after 4 weeks, versus 0 of 15 on placebo. #### Fewer Night-Time Voids A placebo-controlled crossover RCT (each participant receives both treatments in turn) in 40 adults aged 50 or older with nocturia (waking at night to urinate) tested 50 mg/day of a nobiletin–tangeretin mix for 6 weeks ([Ito et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37109094/)). Bladder capacity, the trial's main outcome, did not change. **Magnitude:** 0.5 fewer night-time voids per night than placebo with the nobiletin–tangeretin mix. #### Blood Cholesterol ⚠️ Conflicted A manufacturer-affiliated Sytrinol trial (citrus-peel flavones plus tocotrienols, vitamin E relatives) reported large falls ([Roza et al., 2007](https://pubmed.ncbi.nlm.nih.gov/17985810/)); a juice-company-co-authored enriched-juice trial lowered LDL-C (low-density lipoprotein cholesterol) more than placebo ([Navajas-Porras et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40597485/)). A larger independent trial found none ([Schuchardt et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25828621/)). Net reading: cholesterol benefit unproven. **Magnitude:** LDL-C fell 5.2% with the higher-flavone dose versus 4.2% with placebo over 12 weeks (no significant difference); the manufacturer-affiliated trial reported 19–27% falls. #### Blood Sugar Control In 44 adults with obesity on a calorie-restricted diet, orange juice enriched with nobiletin, sinensetin and tangeretin lowered HbA1c (glycated hemoglobin, a three-month blood sugar average) more than placebo juice ([Navajas-Porras et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40597485/)). A juice-company employee co-authored it. Rodent studies show improved insulin sensitivity. **Magnitude:** HbA1c fell significantly more with the enriched juice than with placebo juice over 6 weeks; the published abstract reports no between-group outcome figure. #### Survival in Brain Cancer (as Part of a Mixture) A randomized phase II (mid-stage efficacy) trial in 53 people with glioblastoma (an aggressive brain cancer) added a seven-ingredient capsule containing tangeretin to standard treatment for one year ([Rooprai et al., 2026](https://pubmed.ncbi.nlm.nih.gov/41760279/)). Survival did not differ from placebo; other anticancer data come from cells and animals. **Magnitude:** Median overall survival was 14 months with the nutrient capsule versus 13 months with placebo (not statistically significant). ### Speculative 🟨 #### Longer Lifespan in Worms Tangeretin extended mean lifespan and heat-stress resistance in *Caenorhabditis elegans* worms through the insulin/IGF-1 pathway ([Liu et al., 2022](https://pubmed.ncbi.nlm.nih.gov/34580918/)). No mammalian lifespan or human aging data exist; the basis is animal only. #### Brain Protection Rodent studies show tangeretin protects nerve cells and memory in stroke, toxin, Alzheimer's and Parkinson's models ([review by Matsuzaki & Ohizumi, 2021](https://pubmed.ncbi.nlm.nih.gov/33406641/)). No human cognitive trial exists; the basis is animal and cell work. #### Reduced Clot Formation Tangeretin blocked human platelet activation and clot formation under flow in the laboratory ([Vaiyapuri et al., 2013](https://pubmed.ncbi.nlm.nih.gov/24135020/)). No human clotting or cardiovascular outcome data exist; the basis is laboratory and animal only. #### Kidney Protection After Injury In a mouse kidney ischemia-reperfusion model (damage when blood flow returns after a blockage), tangeretin reduced kidney injury by suppressing NF-κB inflammatory signaling ([Gao et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40682983/)). The basis is animal only. ## Benefit-Modifying Factors - **Genetic polymorphisms:** CYP1A2 activity varies several-fold between people, partly through variants such as CYP1A2*1F and partly through smoking; this may change how long tangeretin stays in the blood. No study has tested response by genotype. - **Baseline biomarkers:** In the independent cholesterol trial ([Schuchardt et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25828621/)), adults with raised LDL-C and hs-CRP (high-sensitivity C-reactive protein, a blood inflammation marker) saw no benefit; athlete signals appeared under high training stress, suggesting effects may depend on a stressed baseline. - **Sex:** Trials enrolled mostly men; the airway trial ([Cao et al., 2024](https://pubmed.ncbi.nlm.nih.gov/39422600/)) included 14 women and the nocturia trial ([Ito et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37109094/)) 13, but neither reported sex-specific results, so sex differences in benefit are unknown. - **Pre-existing conditions:** Signals come from specific groups (athletes with exercise-induced airway narrowing, older adults with nocturia, people with obesity) and may not transfer to healthy adults. - **Age:** The nocturia trial (mean age 73.5; [Ito et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37109094/)) is the only data in older adults; athlete trials enrolled young adults, so benefits at the older end of the target range are largely untested. - **Meal fat and formulation:** Tangeretin is fat-soluble; emulsion delivery raised blood levels 4- to 20-fold in rats ([Hu et al., 2021](https://pubmed.ncbi.nlm.nih.gov/33356230/)), so formulation and a fat-containing meal likely shape the dose that is absorbed. ## Potential Risks & Side Effects ### High 🟥 🟥 🟥 No risk reaches High: no human trial or case series has documented a clinical adverse event attributable to tangeretin; the evidence consists of one case report, one juice interaction study, and animal and laboratory work. ### Medium 🟥 🟥 No risk reaches Medium: no single trial or consistent observational dataset has recorded an adverse event from tangeretin; the small human trials reported none, and interaction signals come from indirect or animal data. ### Low 🟥 #### Altered Drug Absorption and Metabolism Tangeretin stimulates CYP3A4, alters CYP1A2 and inhibits P-glycoprotein (P-gp, a pump expelling drugs from cells) in laboratory studies. In eight healthy volunteers, tangerine juice delayed absorption of the sedative midazolam without changing total exposure ([Backman et al., 2000](https://pubmed.ncbi.nlm.nih.gov/10801247/)). Supplement doses remain untested. **Magnitude:** Tangerine juice lowered midazolam exposure over the first 1.5 hours by 39% while leaving total exposure unchanged. #### Low Platelet Count With Citrus Flavonoid Supplements A French drug-safety report described thrombocytopenic purpura (low platelets causing skin bleeding spots) in a person taking two supplements made mainly of citrus flavonoids ([Ghali et al., 2015](https://pubmed.ncbi.nlm.nih.gov/26242500/)). Tangeretin's specific role and causation were not established. **Magnitude:** Not quantified in available studies. Only a single case report exists, so no frequency can be estimated. ### Speculative 🟨 #### Weakened Tamoxifen Effect in Breast Cancer In mice with human breast tumors, tangeretin abolished the tumor control of tamoxifen (an estrogen-blocking breast cancer drug), cutting median survival from 56 to 14 weeks ([Bracke et al., 1999](https://pubmed.ncbi.nlm.nih.gov/10050869/)). The basis is animal only. #### Increased Bleeding Tendency Tangeretin inhibited human platelet function in the laboratory and reduced blood clotting in mice ([Vaiyapuri et al., 2013](https://pubmed.ncbi.nlm.nih.gov/24135020/)). No human bleeding events are reported; the basis is laboratory and animal only. #### Reduced Anticancer Immune Activity Tangeretin reduced natural killer cell (immune cells that destroy tumor cells) activity in the laboratory ([Bracke et al., 1999](https://pubmed.ncbi.nlm.nih.gov/10050869/)) and their number in mice ([Depypere et al., 2000](https://pubmed.ncbi.nlm.nih.gov/11056327/)). The basis is laboratory and animal only. #### Excess Blood Sugar Lowering With Diabetes Drugs Tangeretin blunted post-meal glucose rises in mice by blocking gut glucose uptake ([Satsu et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34684383/)), so additive hypoglycemia (abnormally low blood sugar) with glucose-lowering drugs is plausible. The basis is animal and mechanistic only. ## Risk-Modifying Factors - **Genetic polymorphisms:** Variants in CYP1A2, the main clearing enzyme, and ABCB1 (the gene encoding P-gp) could raise or lower tangeretin and co-medication levels; no human study has tested side effects by genotype. - **Baseline biomarkers:** A low platelet count or raised INR (international normalized ratio, a clotting-time measure) narrows the margin for tangeretin's platelet-inhibiting effect seen in laboratory studies. - **Sex:** Women with hormone receptor-positive breast cancer carry the tamoxifen-interaction concern; the small mixed-sex trials report no other sex differences in side effects. - **Pre-existing conditions:** Bleeding disorders, liver disease (slower CYP1A2 clearance), organ transplantation on narrow-margin drugs, and active cancer treatment raise interaction and bleeding concerns. - **Age:** Older adults tolerated 50 mg/day in the nocturia trial (mean age 73.5; [Ito et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37109094/)), but more concurrent medications at older ages raise interaction exposure. ## Key Interactions & Contraindications **Prescription drugs:** - **Selective estrogen receptor modulators (estrogen-blocking drugs such as tamoxifen, toremifene):** Avoid (precautionary contraindication). In mice tangeretin abolished tamoxifen's tumor control; no human data exist. No mitigation other than avoidance is known. - **Anticoagulants and antiplatelet drugs (blood thinners such as warfarin, apixaban, rivaroxaban, clopidogrel):** Caution. Additive bleeding risk is plausible from platelet inhibition. An INR check within 1 week of starting or stopping on warfarin detects changes; unusual bruising is the early sign. - **Narrow-margin CYP3A4 substrates (drugs cleared by CYP3A4, such as cyclosporine, tacrolimus, simvastatin, midazolam):** Monitor. Laboratory CYP3A4 stimulation could lower drug levels; tangerine juice only delayed absorption. Drug-level checks 1–2 weeks after starting or stopping detect shifts. - **CYP1A2 substrates (theophylline, clozapine, tizanidine, caffeine):** Caution. Tangeretin inhibits or induces CYP1A2 in laboratory studies, so drug levels may rise or fall. Drug-level or effect monitoring after starting detects shifts. - **P-gp substrates and chemotherapy (digoxin, dabigatran, paclitaxel, doxorubicin):** Caution; use during chemotherapy is generally left to the oncology team. P-gp inhibition may raise drug levels and toxicity. Digoxin levels checked 1–2 weeks after starting or stopping detect rises. - **Glucose-lowering drugs (metformin; sulfonylureas, drugs that make the pancreas release insulin, such as glipizide; insulin):** Monitor. Additive glucose lowering is possible; repeated fasting glucose checks in the first 2 weeks detect it. **Over-the-counter medications:** - **NSAIDs (nonsteroidal anti-inflammatory drugs such as ibuprofen, naproxen) and aspirin:** Caution. Additive bleeding risk with platelet inhibition. Occasional rather than regular combined use lowers risk; bruising or gum bleeding is the warning sign. - **Fexofenadine and loperamide (P-gp substrates):** Monitor. P-gp inhibition could raise exposure, strengthening their effects (for loperamide, constipation or, at high doses, heart-rhythm effects); response is the practical gauge when combining. **Supplements:** - **Other citrus flavones and extracts (nobiletin, sinensetin, Sytrinol-type blends, bergamot) and grapefruit juice:** Monitor. Additive CYP and P-gp effects may raise or lower levels of co-administered drugs, and total flavone dose rises; total combined intake is the relevant dose. - **Supplements with additive anticoagulant or antiplatelet effects (fish oil, vitamin E, ginkgo, nattokinase, curcumin):** Caution. Additive platelet inhibition may increase bruising and bleeding; stacking them before procedures raises bleeding exposure. - **Supplements with additive glucose-lowering effects (berberine, chromium, cinnamon extract):** Monitor. Additive blood sugar lowering, especially alongside diabetes drugs; fasting glucose checks detect it. **Other interventions:** - **Surgery and dental procedures:** Caution. Possible bleeding from platelet inhibition; the [Natural Medicines monograph for methoxylated flavones](https://www.rxlist.com/supplements/methoxylated_flavones.htm) lists stopping at least 2 weeks before scheduled surgery. **Populations who should avoid Tangeretin:** - People with hormone receptor-positive breast cancer taking tamoxifen or other endocrine therapy (hormone-blocking cancer drugs) - People receiving chemotherapy, unless the oncology team approves - Pregnant or breastfeeding women (no safety data beyond food amounts) - People with bleeding disorders or a platelet count below 100 × 10⁹/L - People on warfarin with an unstable INR (outside the prescribed range, e.g., above 3.0) - Organ transplant recipients taking cyclosporine or tacrolimus - People with liver cirrhosis rated Child-Pugh Class B or C (a liver-disease severity score), given reduced CYP1A2 clearance - People within 2 weeks of scheduled surgery - Children and adolescents under 18 (no data) ## Risk Mitigation Strategies - **Medication screen before starting:** A review of all drugs for tamoxifen, anticoagulants, antiplatelet drugs, and narrow-margin CYP3A4, CYP1A2 or P-gp substrates before starting prevents unrecognized drug interactions. - **Low starting dose:** Starting at 50 mg/day (the nocturia trial dose) for 2 weeks before moving to 200 mg/day limits the size of any drug-handling or platelet effect while tolerance is assessed. - **Clotting safeguards:** An INR check within 1 week of starting or stopping (warfarin users) and a 2-week pause before scheduled surgery (all users) mitigate bleeding risk. - **Glucose checks with diabetes drugs:** Fasting glucose measured 3–4 times in the first 2 weeks mitigates hypoglycemia from additive glucose lowering. - **Baseline and follow-up labs:** A complete blood count at baseline and 8–12 weeks detects the low platelet count reported with citrus flavonoid supplements; liver enzymes flag liver disease that would slow clearance of tangeretin and interacting drugs. - **Human-grade products only:** Using third-party tested supplements rather than chemicals labeled "for research use only" keeps the actual dose known, so drug-interaction and bleeding risks are not raised by mislabeled or excess tangeretin. - **Time-limited use:** Courses matching studied durations (4–12 weeks), followed by reassessment, limit cumulative exposure to the untested drug-interaction and platelet effects. ## Therapeutic Protocol - **Single-agent dosing:** 200 mg/day tangeretin orally for 4 weeks is the only dose studied alone in humans, from Shanghai University of Sport athlete trials ([Liu et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35665223/)); no longevity-specific dose has been established. - **Nobiletin–tangeretin mixture:** 50 mg/day of a mix from *Citrus depressa* (shiikuwasa, an Okinawan citrus) peel for 6 weeks, used in the Kyoto nocturia trial ([Ito et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37109094/)) and popularized through Japanese shiikuwasa extracts. - **Citrus-flavone blends:** Sytrinol-type blends pair mixed citrus flavones (32–270 mg/day in trials) with palm tocotrienols; developed commercially in Canada, with independent testing at 32–103 mg/day finding no cholesterol benefit ([Schuchardt et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25828621/)). - **Whole-food approach:** Citrus zest and dried mandarin peel supply tangeretin at low, variable levels (roughly 10–300 mg per kg fresh tangerine peel); no trial has tested food-level intake. - **Time of day:** Trials did not compare timing. Taking it with the day's largest fat-containing meal is a practical default consistent with its fat solubility. - **Half-life:** Human half-life is unmeasured; in rats it is about 5.7 hours, with peak blood levels 5–6 hours after dosing. - **Single vs. split dose:** All human trials used once-daily dosing; splitting 200 mg into two 100 mg doses with meals fits the rat half-life but is untested. - **Genetic considerations:** People with high CYP1A2 activity (smokers, CYP1A2*1F carriers) may clear tangeretin faster; no genotype-guided dosing exists. - **Sex differences:** No sex-based dosing differences are known; women with hormone-sensitive breast cancer are excluded because of the tamoxifen concern. - **Age:** Older adults tolerated 50 mg/day ([Ito et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37109094/)); starting at 50 mg with a medication review fits higher interaction exposure at older ages. - **Baseline biomarkers:** Elevated fasting glucose, HbA1c or training-related stress markers leave the most room for measurable change; normal values may show little response. - **Pre-existing conditions:** Liver disease may slow clearance; bleeding disorders and anticoagulant use call for clotting monitoring before and during use. ## Discontinuation & Cycling - **Short-term, not lifelong:** Human data cover 4–12 weeks (one year only within a brain cancer mixture trial); continuous lifelong use is untested, so use is framed as a time-limited trial with reassessment. - **Withdrawal effects:** None reported, and no dependence mechanism is known. - **Tapering:** Not required; people on narrow-margin CYP3A4 or CYP1A2 drugs recheck drug levels 1–2 weeks after stopping, as enzyme effects reverse. - **Cycling:** No evidence that cycling maintains efficacy; 4-week courses mirror the trials, and off-periods of 2 or more weeks allow benefit to be reassessed. - **Before surgery:** A pause of at least 2 weeks before scheduled procedures addresses possible platelet effects. ## Sourcing and Quality - **Product form:** Standalone tangeretin supplements are scarce; most products are citrus-peel extracts standardized to mixed flavones (nobiletin, tangeretin, sinensetin), so the tangeretin dose must be calculated from the label. - **Purity:** Quality markers include at least 95% purity confirmed by HPLC (high-performance liquid chromatography, a laboratory purity test) on a batch certificate of analysis, plus heavy-metal and solvent-residue testing. - **Research-grade chemicals:** Suppliers such as LKT Laboratories and Aphios sell tangeretin labeled for research use, not human consumption, and not made under supplement manufacturing standards. - **Third-party testing:** NSF International, USP (United States Pharmacopeia) or Informed Sport certification verifies label accuracy and contaminants; Informed Sport matters for athletes subject to anti-doping testing. - **Branded ingredients:** Sytrinol and Japanese shiikuwasa extracts are the best-documented branded sources; their tangeretin content varies with cultivar and harvest. - **Formulation:** Oil-filled softgels or emulsions may absorb better than dry powder capsules, given tangeretin's poor water solubility. ## Practical Considerations - **Time to effect:** Human trials measured changes at 4–6 weeks; cholesterol and blood sugar trials ran 6–12 weeks, so shorter periods are unlikely to show an effect. - **Common pitfalls:** Assuming citrus juice supplies meaningful tangeretin (it is concentrated in peel), combining it with tamoxifen, anticoagulants or antiplatelet drugs, and extrapolating laboratory anticancer results to people. - **Regulatory status:** In the US it is sold as a dietary supplement ingredient, not a drug approved by the FDA (US Food and Drug Administration); no health claim is authorized. - **Cost and accessibility:** Purified tangeretin is mainly sold as a costly research chemical; human-grade single-ingredient products are hard to find, so most access comes through citrus-peel blends. - **Evidence concentration:** The single-agent athlete trials come from one research group; independent replication is absent. ## Interaction with Foundational Habits - **Sleep:** Indirect, potentially supportive. The nobiletin–tangeretin mix reduced night-time voiding in older adults ([Ito et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37109094/)), which may reduce sleep interruption. Sister compound nobiletin strengthens body-clock rhythms in mice, but tangeretin did not consistently do so in blood-vessel tissue ([Yang et al., 2026](https://pubmed.ncbi.nlm.nih.gov/41355044/)). No direct sleep-quality trial exists. - **Nutrition:** Direct. Tangeretin is fat-soluble, so intake with a fat-containing meal likely improves absorption. Citrus zest and dried mandarin peel are dietary sources. Grapefruit and bitter orange juices add further CYP3A4 effects. No nutrient depletion is known. - **Exercise:** Tentatively supportive. In athletes, 200 mg/day lowered cortisol after heavy lifting without changing strength ([Liu et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35665223/)). In mice it raised endurance through AdipoR1 (adiponectin receptor 1, a receptor for a fat-derived metabolic hormone) ([Li et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38990695/)). No evidence shows blunted training adaptation. - **Stress management:** Direct, hormonal. Tangeretin lowered cortisol and ACTH responses to intense exercise stress in one trial ([Liu et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35665223/)). No human data exist on psychological stress, mood or anxiety, so effects beyond exercise stress are unknown. ## Monitoring Protocol & Defining Success Baseline testing before starting establishes reference values for the effects tangeretin may have on clotting, blood sugar, blood fats and drug handling. It includes a complete blood count with platelets; liver enzymes ALT (alanine aminotransferase) and AST (aspartate aminotransferase); eGFR (estimated glomerular filtration rate, a kidney-function estimate); fasting glucose and HbA1c; a lipid panel with LDL-C; and hs-CRP. Warfarin users add INR, and people on narrow-margin drugs add trough levels (the lowest level before the next dose). Ongoing monitoring repeats the blood count, liver enzymes, fasting glucose, HbA1c and lipids at 8–12 weeks, then every 6–12 months if use continues. Warfarin users recheck INR within 1 week of starting or stopping, and users of narrow-margin drugs recheck drug levels 1–2 weeks after any change. Success means a measurable improvement in the target marker or symptom without new bruising, bleeding or laboratory abnormalities. | Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes | |-----------|--------------------------|-----------------|---------------| | Platelet count | 200–350 × 10⁹/L | Bleeding safety | Conventional range 150–450 × 10⁹/L; part of the complete blood count | | ALT | Under 25 U/L | Liver strain | Conventional upper limit about 40–55 U/L; morning draw | | AST | Under 25 U/L | Liver or muscle strain | Conventional upper limit about 40 U/L; avoid hard exercise 48 hours before, as it raises AST | | eGFR | Above 90 mL/min/1.73 m² | Kidney clearance | Conventional threshold above 60; pair with creatinine and cystatin C | | Fasting glucose | 75–90 mg/dL | Blood sugar effect | Conventional 70–99 mg/dL; 8–12 hour fast, morning draw | | HbA1c | Under 5.4% | Three-month sugar trend | Conventional under 5.7%; pair with fasting glucose | | LDL-C | Under 100 mg/dL; under 70 mg/dL with elevated cardiovascular risk | Cholesterol claim | Conventional under 130 mg/dL; fasting lipid panel, pair with apolipoprotein B | | hs-CRP | Under 1.0 mg/L | Inflammation trend | Conventional under 3.0 mg/L; retest if drawn during acute illness | | INR (warfarin users only) | No functional target; the prescriber's range (usually 2.0–3.0) applies | Bleeding risk | Checked within 1 week of starting or stopping tangeretin | | Morning cortisol (optional) | No established target; track change from the individual's own baseline | Stress-hormone response | Conventional about 6–23 µg/dL at 8 a.m.; draw 7–9 a.m., avoid training beforehand | Qualitative markers: - Sleep continuity: night-time awakenings and voids - Recovery after hard training: soreness and perceived fatigue - Energy levels and cognitive clarity - Bruising, nosebleeds or bleeding gums (safety) - Digestive comfort ## Emerging Research - **Enriched juice trial:** Effect of Citrus Flavonoids on Obesity ([NCT06680635](https://clinicaltrials.gov/study/NCT06680635)). Completed placebo-controlled RCT of 80 adults with obesity, with or without type 2 diabetes, testing nobiletin-, sinensetin- and tangeretin-enriched juice plus a low-calorie diet for 8 weeks; primary focus on blood sugar and insulin resistance. Diabetic-subgroup results could strengthen or weaken the signal. - **Unripe ponkan extract:** Effects of unripe *Citrus reticulata* fruit extract on body weight and body fat ([NCT05620667](https://clinicaltrials.gov/study/NCT05620667)). 300 overweight adults drink unripe ponkan (a flavone-rich mandarin) extract; main outcome body weight at 8 weeks, with or without time-restricted eating (eating within a daily 8-hour window); status unknown since its 2022 start. - **Nocturia confirmation (no NCT ID):** The nobiletin–tangeretin nocturia trial ([Ito et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37109094/)) was registered in Japan rather than on ClinicalTrials.gov; a larger confirmatory trial would test whether the modest reduction in night-time voids holds. - **Better absorption:** [Biopolymer Additives Enhance Tangeretin Bioavailability in Emulsion-Based Delivery Systems: An In Vitro and In Vivo Study](https://pubmed.ncbi.nlm.nih.gov/33356230/) (Hu et al., 2021) found emulsions raised rat blood levels 4- to 20-fold, which could make effective human doses practical. - **Aging biology:** [Identification and evaluation of citrus peel-derived polymethoxyflavonoids as natural SIRT1 activators](https://pubmed.ncbi.nlm.nih.gov/42225042/) (Ko et al., 2026) found tangeretin activates SIRT1 (sirtuin 1, an enzyme linked to cellular stress resistance) in enzyme assays; mammalian lifespan studies remain absent. - **Body-clock effects (weakening):** [Pharmacological modulation of circadian rhythms in brain microvasculature](https://pubmed.ncbi.nlm.nih.gov/41355044/) (Yang et al., 2026) found that, of the citrus flavones tested, only sinensetin consistently strengthened rhythms; tangeretin did not, tempering assumptions borrowed from nobiletin. - **Cancer (weakening):** [Overall Survival of Glioblastoma Patients Treated With a Combination of 7 Micronutrients: A Nutraceutical Trial](https://pubmed.ncbi.nlm.nih.gov/41760279/) (Rooprai et al., 2026) found no survival benefit; the tamoxifen interaction seen in mice has not been studied in people. - **Athlete replication:** [The impact of tangeretin combined with whey protein on exercise-induced bronchoconstriction in professional athletes: a placebo-controlled trial](https://pubmed.ncbi.nlm.nih.gov/39422600/) (Cao et al., 2024) used a placebo without whey; the same group's whey-controlled sprinter trial ([Cao et al., 2026](https://pubmed.ncbi.nlm.nih.gov/41509539/)) did not test airways, so independent whey-matched replication is still lacking. ## Conclusion Tangeretin is a plant compound concentrated in citrus peel, available mainly through citrus-peel extracts and a few purified products. It draws interest because laboratory and animal studies show broad effects on inflammation, blood sugar, brain cells, blood clotting and, in worms, lifespan. For health-focused adults, the human evidence is thin. Small, short trials, most from a single research group or testing mixtures, suggest a calmer stress-hormone response to hard training (not seen in a second athlete trial), less exercise-triggered airway narrowing in athletes, fewer night-time trips to urinate in older adults, and possibly better blood sugar. None of these has been confirmed independently. Body composition and strength changed little or inconsistently. The cholesterol claim rests on a trial by people linked to the product's makers, while a larger independent trial found no benefit, and a juice trial was co-authored by a juice-company employee. The main risks are uncertain rather than documented. Mouse work suggests tangeretin can cancel the benefit of a common breast cancer drug, and laboratory work suggests it can slow blood clotting and change how the liver and gut handle some medicines. No serious side effects have been reported in the small human studies, but long-term safety is unknown. Overall, tangeretin is an early-stage compound: its biology is intriguing, its human benefits are small and unconfirmed, and its safety questions center on specific drug combinations rather than on the compound alone. **[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**